Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lorus Therapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: DaveAu who wrote (218)	12/8/1998 11:10:00 AM
From: Moneysmith	Read Replies (1) \| Respond to of 279

Some recent news:............................. 1 09:18 T Imutec Reports Positive Virulizin Phase I/II Trial Results TORONTO (Dow Jones)--Imutec Pharma Inc. (IMUTF) said it has received "positive" immunological data from its Virulizin Phase I/II pancreatic cancer trial in Chicago. In a news release, the company said these results are in addition to the positive clinical trial results and supporting pre-clinical studies announced earlier this year. Imutec said monocytes and lymphocytes collected from pancreatic cancer patients during Virulizin treatment showed an increased capacity to mediate tumor cell killing in vitro. It said the function of the natural killer cell component of the immune system was also increased in patients during therapy, and appeared to be associated with overall patient survival. "These data suggest that Virulizin has adjuvant-like properties in vivo when administered to cancer patients," said Dr. Donald Braun, director of Scientific Program Development at the Rush Cancer Institute in Chicago. Virulizin is an activator of human macrophages, which stimulates the release of cytokines resulting in an induction of tumoricidal function. Imutec said the final Phase I/II trial data shows an overall median survival of 6.71 months, and the six-month survival rate of 58%. These results confirm and extend previous studies performed by the company in Canada in pancreatic cancer patients. In the main Phase II trial of Gemzar in patients with 5-FU refractory pancreatic cancer, the median survival was 3.85 months with a six-month survival of 31%. It said the results of the recent trial document that "Virulizin has clinical activity that is at least as good as what has been reported for Gemzar, in previously treated patients, with a much better safety profile." Imutec Pharma, which is in the process of changing its name to Lorus Therapeutics Inc., is a pharmaceutical company. (END) DOW JONES NEWS 12-08-98